USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: VISDEX CORPORATION
Address: 1751 CAPISTRANO AVE
BERKELEY, CA 94707-
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: (510) 589-8033

Award Totals:

Program/Phase Award Amount ($) Number of Awards
STTR Phase I $772,388.00 3
STTR Phase II $1,446,393.00 2

Award List:

Novel Treatment for Degenerative Myopia

Award Year / Program / Phase: 2006 / STTR / Phase I
Agency: HHS
Research Institution: CALIFORNIA INSTITUTE OF TECHNOLOGY
Principal Investigator: Julia A. Kornfield
Award Amount: $270,496.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Photopolymerization has provided a powerful tool for tissue engineering through localized synthesis of therapeutic materials in situ. To date, strategies to create photopolymerized networks on the surface of a tissue, such as the inner lumen of a blood vessel or… More

Novel Treatment for Degenerative Myopia

Award Year / Program / Phase: 2008 / STTR / Phase II
Agency: HHS
Research Institution: N/A
Principal Investigator:
Award Amount: $645,867.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Myopia affects 30% of the population in the U.S. and Europe, and 70-90% of the population in some Asian countries. High myopia of greater than 8 diopters affects 0.2 0.4% of the US population and up to 1% of the pop ulation in Asian countries. The principal… More

Novel Treatment for Post-LASIK Ectasia

Award Year / Program / Phase: 2009 / STTR / Phase I
Agency: HHS
Research Institution: CALIFORNIA INSTITUTE OF TECHNOLOGY
Principal Investigator: Matthew S. Mattson
Award Amount: $347,984.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Of the 1.4 million refractive surgeries performed each year using laser assisted in situ keratomileusis (LASIK) in the U.S., 1 in 2500 will result in post-LASIK ectasia-a thinning and bulging of the cornea analogous to keratoconus that becomes evident months or… More

Characterization of Exudative Macular Degeneration and Diabetic Retinopathy Using

Award Year / Program / Phase: 2010 / STTR / Phase I
Agency: HHS
Research Institution: California Institute Of Technology
Principal Investigator: Scott E. Fraser – 626-395-2790
Award Amount: $153,908.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Since its first use in the retina in 1961, fluorescein angiography (FA) has been the gold standard for objective characterization of retinovascular disease (e.g. diabetic retinopathy, retinal vein occlusions, and choroidal neovascularization associated with… More

Phase Contrast OCT for Non-Invasive Imaging of Retinovascular Disease

Award Year / Program / Phase: 2013 / STTR / Phase II
Agency: HHS
Research Institution: UNIVERSITY OF CALIFORNIA, DAVIS
Principal Investigator: Scott E. Fraser – 626-395-2790
Award Amount: $800,526.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Since its introduction in the 1960's, fluorescein angiography (FA) has been the gold standard for retinal vascular diagnosis. However, FA is costly, invasive, and time-consuming, which limits its usefulness as a screening tool. As a potential non-invasive… More